Mayo Foundation for Medical Education and Research

Michael P Gustafson

Allan B Dietz

Greg W Butler

Edward B Leof

Andrew H Limper

Charles F Thomas

Yi Lin

This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided.

Compositions containing platelet contents

This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4lymphocytes, CD8lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14HLA-DRmonocytes, and/or CD86monocytes per unit volume (e.g., cells per μL or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

Methods and materials for assessing immune system profiles

This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4lymphocytes, CD8lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14HLA-DRg monocytes, and/or CD86monocytes per unit volume (e.g., cells per &#x3bc;L or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

This document provides methods and materials for treating patients following an assessment of immune subtypes such as an assessment of peripheral blood phenotypes. For example, methods and materials for treating a mammal having a medical condition after assessing a mammal's level of CD14+/DR&#x2212; cells (e.g., CD14+/DR&#x2212; monocytes) and level of CD4+ cells (e.g., CD4+ T cells) and classifying the mammal has being likely to experience a favorable or unfavorable medical outcome based at least in part on the mammal's level of CD14+/DR&#x2212; cells and level of CD4+ cells are provided.

Treating patients based on immune subtypes

This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4lymphocytes, CD8lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14HLA-DRmonocytes, and/or CD86monocytes per unit volume (e.g., cells per &#x3bc;L or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

A nucleic acid and corresponding polypeptide that aids in the regulation of the cell cycle in Pneumocystis carinii is described. Antibodies generated against a unique carboxyl-terminus region of the polypeptide have specific binding affinity for P. carinii Cdc2 polypeptide and are benificial in diagnosing and monitoring P. carinii infection in patients. Expression of P. carinii Cdc2 polypeptide in cdc2-mutant yeast and other cdc2-mutant organisms provides a for model for studying the life cycle of P. carinii and for identifying novel therapeutics.

Cdc2 protein kinase from pneumocystis carinii

A nucleic acid and corresponding polypeptide that aids in the regulation of the cell cycle in Pneumocystis carinii is described. Antibodies generated against a unique carboxyl-terminus region of the polypeptide have specific binding affinity for P. carinii Cdc2 polypeptide and are beneficial in diagnosing and monitoring P. carinii infection in patients. Expression of P. carinii Cdc2 polypeptide in cdc2-mutant yeast and other cdc2-mutant organisms provides a useful model for studying the life cycle of P. carinii and for identifying novel therapeutics.

Growing community of inventors

Rochester, MN, United States of America

Michael P Gustafson